Squarepoint’s Sagimet Biosciences SGMT Stock Holding History

Squarepoint’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$222K	Buy	+22,441	New	+$206K	﹤0.01%	4001
2026 Q2	–	Sell	-118,620	Closed	-$620K	–	4922
2026 Q1	$620K	Buy	118,620 +33,887	+40%	+$189K	﹤0.01%	3167
2025 Q4	$502K	Buy	84,733 +49,668	+142%	+$357K	﹤0.01%	3219
2025 Q3	$241K	Buy	+35,065	New	+$284K	﹤0.01%	3819
2025 Q1	–	Sell	-50,484	Closed	-$227K	–	5323
2024 Q4	$227K	Buy	50,484 +21,195	+72%	+$107K	﹤0.01%	4373
2024 Q3	$81.1K	Sell	29,289 -65,451	-69%	-$202K	﹤0.01%	3913
2024 Q2	$324K	Buy	+94,740	New	+$435K	﹤0.01%	3387
2023 Q4	–	Sell	-35,000	Closed	-$308K	–	4450
2023 Q3	$308K	Buy	+35,000	New	+$466K	﹤0.01%	3139

Other funds holding SGMT

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint's SGMT Position: Q3 2026 in Review

Squarepoint opened a new position in Sagimet Biosciences (SGMT) in Q3 2026: 22,441 shares worth $222K. The stake represents ﹤0.01% of the portfolio and ranks #4001 among its holdings. This is a return to the name: Squarepoint previously reported a position in SGMT as recently as Q1 2026.

Squarepoint first reported a position in SGMT in Q3 2023 and has held it in 8 quarters since. The position peaked at $620K in Q1 2026. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

Squarepoint held 22,441 shares of Sagimet Biosciences worth $222K as of Q3 2026.
Sagimet Biosciences was a new Squarepoint position in Q3 2026.
Sagimet Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4001 holding.
Squarepoint first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 8 quarters since.
Squarepoint's Sagimet Biosciences position peaked at $620K in Q1 2026.
63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.